Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $15.08 and last traded at $15.07, with a volume of 773113 shares. The stock had previously closed at $14.83.
Takeda Pharmaceutical Trading Up 1.2 %
The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $48.29 billion, a P/E ratio of 37.94, a PEG ratio of 0.24 and a beta of 0.46. The business has a 50 day moving average of $13.59 and a 200-day moving average of $13.90.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.
Institutional Trading of Takeda Pharmaceutical
Institutional investors have recently modified their holdings of the company. Versant Capital Management Inc bought a new position in shares of Takeda Pharmaceutical during the fourth quarter worth about $26,000. Wilmington Savings Fund Society FSB bought a new position in shares of Takeda Pharmaceutical during the 3rd quarter worth approximately $40,000. BNP Paribas Financial Markets raised its holdings in shares of Takeda Pharmaceutical by 416.0% in the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock valued at $46,000 after purchasing an additional 2,596 shares during the last quarter. Farther Finance Advisors LLC lifted its position in shares of Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after purchasing an additional 1,976 shares in the last quarter. Finally, Smithfield Trust Co boosted its holdings in Takeda Pharmaceutical by 76.9% during the third quarter. Smithfield Trust Co now owns 3,428 shares of the company's stock worth $49,000 after purchasing an additional 1,490 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors.
Takeda Pharmaceutical Company Profile
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
See Also
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
